ライフサイエンスコーパス: poor prognosis

1 ssociated with an advanced tumor state and a poor prognosis.

2 requency in human tumors and correlates with poor prognosis.

3 pitope spreading as a potential indicator of poor prognosis.

4 ematopoietic stem cell transplantation has a poor prognosis.

5 ally expressed in GSCs and also predicts GBM poor prognosis.

6 the most common malignancies worldwide with poor prognosis.

7 Pancreatic cancer is a lethal disease with poor prognosis.

8 prognosis and immune-poor TNBC cohorts with poor prognosis.

9 noma (NEC - neuroednocrine carcinoma) with a poor prognosis.

10 AML that arises after RAI treatment has a poor prognosis.

11 ll AML cases and is a subtype that carries a poor prognosis.

12 ated deaths worldwide, mainly because of its poor prognosis.

13 level of lipid synthesis is associated with poor prognosis.

14 characterized by chemotherapy resistance and poor prognosis.

15 ociated with aggressive tumour behaviour and poor prognosis.

16 T2MI is common and associated with poor prognosis.

17 head and neck have few treatment options and poor prognosis.

18 mong transplant recipients, and it carries a poor prognosis.

19 expressed in human lung SCC and portended a poor prognosis.

20 AP4 was increased in human CRC and predicted poor prognosis.

21 outcomes and is an independent predictor of poor prognosis.

22 n counts than did lymphocyte-poor TNBCs with poor prognosis.

23 heterogeneous group of biliary cancers with poor prognosis.

24 decreased expression of FBP1 associated with poor prognosis.

25 healthy individuals and also correlated with poor prognosis.

26 gy, and therapy response and usually predict poor prognosis.

27 ore normal vasculature was associated with a poor prognosis.

28 nd that RBP dysregulation is associated with poor prognosis.

29 ggressive vascular sarcoma with an extremely poor prognosis.

30 rogresses to an aggressive malignancy with a poor prognosis.

31 urvival and function of teeth with otherwise poor prognosis.

32 t for older adults with AML because of their poor prognosis.

33 ile on ruxolitinib therapy may be markers of poor prognosis.

34 d EXO1 expression levels are associated with poor prognosis.

35 le in a cohort of patients with an otherwise poor prognosis.

36 y program, and phagocytosis evasion to offer poor prognosis.

37 with low protein expression of SIRT1 have a poor prognosis.

38 KP expression, AKT S473 phosphorylation, and poor prognosis.

39 colorectal carcinoma and is correlated with poor prognosis.

40 ith early-stage colorectal cancer (CRC) with poor prognosis.

41 Muscle Invasive Bladder Cancer (MIBC) has a poor prognosis.

42 gly associated with histological features of poor prognosis.

43 ly correlates with high (18)F-FDG uptake and poor prognosis.

44 umours that are associated with an extremely poor prognosis.

45 tability has previously been associated with poor prognosis.

46 itive peritoneal cytology) have an extremely poor prognosis.

47 d with both reduced SDHD gene expression and poor prognosis.

48 nocarcinoma, which, once invasive, carries a poor prognosis.

49 r to oesophageal adenocarcinoma, which has a poor prognosis.

50 expression in breast tumors correlated with poor prognosis.

51 alth-related quality of life and yet still a poor prognosis.

52 mmunochemotherapy and transplantation have a poor prognosis.

53 activated in lung cancer and correlates with poor prognosis.

54 a subtype of breast cancer with particularly poor prognosis.

55 ma (PDAC) is an aggressive malignancy with a poor prognosis.

56 pPDH (inactive form of PDH) expression with poor prognosis.

57 ition zones are highly malignant tumors with poor prognosis.

58 ive, treatment resistant and associated with poor prognosis.

59 -NHL) or acute lymphoblastic leukemia have a poor prognosis.

60 childhood brainstem tumor with a universally poor prognosis.

61 es (MDS) are uncommon in children and have a poor prognosis.

62 um- and cetuximab-pretreated population with poor prognosis.

63 mia (AML) is a hematologic malignancy with a poor prognosis.

64 tumours correlating with chemoresistance and poor prognosis.

65 DS gene with concurrent TP53 mutations and a poor prognosis.

66 mmon, aggressive malignancy with universally poor prognosis.

67 L1 is correlated with immune suppression and poor prognosis.

68 curs in 30-50% of MM patients and portends a poor prognosis.

69 to 5% of all cancers and is associated with poor prognosis.

70 ng tumour cells (CTCs), early metastasis and poor prognosis.

71 ny human solid tumors and is associated with poor prognosis.

72 d/or refractory multiple myeloma (RRMM) have poor prognosis.

73 bnormalities previously reported to indicate poor prognosis.

74 at low miR-383 expression is associated with poor prognosis.

75 that overexpresses cyclin D1 with relatively poor prognosis.

76 chronic, progressive fibrotic disease with a poor prognosis.

77 tumor cell proliferation and correlates with poor prognosis.

78 et of patients with this neoplasia that have poor prognosis.

79 creased Th17 frequency was associated with a poor prognosis.

80 predominant infant acute leukemia and has a poor prognosis.

81 mic stem cells (pre-LSCs) is associated with poor prognosis.

82 es that high APAK expression correlates with poor prognosis.

83 refore contributes to lung tumorigenesis and poor prognosis.

84 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis.

85 cess of perineural invasion, which carries a poor prognosis.

86 ll infant acute leukemias and are markers of poor prognosis.

87 with end-stage liver disease and portends a poor prognosis.

88 is found in tumor samples from patients with poor prognosis.

89 sociated with more aggressive phenotypes and poor prognosis.

90 haracterizes a subgroup of HCC patients with poor prognosis.

91 onclusion Children with metastatic HB have a poor prognosis.

92 s, and RUNX1 mutations are associated with a poor prognosis.

93 a (OAC) is increasing in incidence and has a poor prognosis.

94 eoperative Pe blood predicted a trend toward poor prognosis.

95 verse human cancers and is associated with a poor prognosis.

96 Smad4 immunoexpression showed a trend toward poor prognosis.

97 with an inflammatory molecular signature and poor prognosis.

98 were prone to have poor differentiation and poor prognosis.

99 urs, and its upregulation is associated with poor prognosis.

100 yps and colon cancer and was associated with poor prognosis.

101 mon in acute heart failure (HF) and portends poor prognosis.

102 is a hypervascular primary brain tumor with poor prognosis.

103 ted in gastric cancer and is associated with poor prognosis.

104 ere inflammation, predisposing patients to a poor prognosis.

105 (NF-kappaB) p65-->ZEB1 pathway and confers a poor prognosis.

106 levels of pro-inflammatory cytokines predict poor prognosis.

107 ll one of the deadliest cancers, with a very poor prognosis.

108 neo)adjuvant chemotherapy fails to improve a poor prognosis.

109 cell lung cancer (NSCLC) are associated with poor prognosis.

110 expression is linked to high metastasis and poor prognosis.

111 ith aggressive disease, drug resistance, and poor prognosis.

112 YCN is associated with high-risk disease and poor prognosis.

113 DLBCL and MCL had a poor prognosis (5-year DSS, 21% and 50%, respectively),

114 tory muscle weakness is a known predictor of poor prognosis, a comprehensive comparison of different

115 t JAK2 inhibitors might be most effective in poor prognosis ABC-DLBCL, which shows higher levels of I

116 gliomas given the increased risk of ICH and poor prognosis after a major hemorrhage on anticoagulati

117 the Milan criteria, 2714 were shown to have poor prognosis after transplantation after stratificatio

118 ability-high (MSI-H) colorectal cancer has a poor prognosis after treatment with conventional chemoth

119 s with HCC expressing reduced DDX5 exhibited poor prognosis after tumor resection, identifying DDX5 a

120 transplantation models, and correlates with poor prognosis among breast cancer patients.

121 ic leukemia (ALL) is characterized by a very poor prognosis and a high likelihood of acquired chemo-r

122 nic transcription factor, is associated with poor prognosis and a strong risk of metastasis compared

123 Wnt5a overexpression, which correlated with poor prognosis and also discriminated infiltrating mesen

124 Patients with heart failure (HF) have a poor prognosis and are categorized by ejection fraction

125 arly stages of lung cancer are predictive of poor prognosis and can be interrogated to determine biom

126 ker keratin 19 (K19) have been linked with a poor prognosis and exhibit an increase in platelet-deriv

127 othelioma is a highly aggressive cancer with poor prognosis and few treatment options following progr

128 Patients with advanced sarcomas have a poor prognosis and few treatment options that improve ov

129 Hodgkin lymphomas frequently associated with poor prognosis and for which genetic mechanisms of trans

130 portant to identify key pathways that confer poor prognosis and guide potential targeted therapy.

131 rate-refractory prostate cancer (CRPC) has a poor prognosis and high morbidity.

132 s its progression and is strongly related to poor prognosis and high mortality risk.

133 east cancer (TNBC) patients commonly exhibit poor prognosis and high relapse after treatment, but the

134 a subtype of this malignancy associated with poor prognosis and high risk of relapse.

135 WS: n = 99 patients), TF was associated with poor prognosis and increased risk of blood vessel infilt

136 cancer is an aggressive subtype that confers poor prognosis and is found largely within the clinical

137 cell renal cell carcinoma (ccRCC) confers a poor prognosis and is of unknown pathogenesis.

138 tory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and limited treatment options.

139 mplification is the most reliable marker for poor prognosis and MYCN overexpression in embryonic mous

140 ighly aggressive, heterogeneous disease with poor prognosis and no effective targeted therapies.

141 scription factor-2 (ZEB2) is correlated with poor prognosis and patient outcome in a variety of human

142 Epithelial ovarian cancer (EOC) has poor prognosis and rapid recurrence because of widesprea

143 ssion of the ErbB2/HER2 oncogene, conferring poor prognosis and resistance to endocrine therapy.

144 nd KRAS mutation is commonly associated with poor prognosis and resistance to therapy.

145 enocarcinoma, which has been associated with poor prognosis and resistant to non-surgery therapy comp

146 We identify the factors associated with a poor prognosis and those that can guide diagnostic testi

147 ophageal squamous cell carcinoma (ESCC) with poor prognosis, and elevation of its expression contribu

148 nts with acute myeloid leukemia (AML) have a poor prognosis, and innovative maintenance therapy could

149 solid histology, liver and bone metastasis, poor prognosis, and potential responsiveness to Notch1 i

150 e kinase are common mutations in AML, confer poor prognosis, and stimulate myeloproliferation.

151 levated LINC00473 expression correlated with poor prognosis, and sustained LINC00473 expression was r

152 Renal cell carcinoma (RCC) is a cancer with poor prognosis, and the 5-year survival rate of patients

153 Both groups are associated with a very poor prognosis, and these patients are among those who c

154 rapeutics, esophageal cancer still carries a poor prognosis, and thus, there remains a need to elucid

155 disease-related morbidities associated with poor prognosis, and were refractory to oxaliplatin and i

156 with low MFN2 expression are associated with poor prognosis as compared to patients with high MFN2 ex

157 loads during the acute phase of illness had poor prognosis at the post-acute phase with more restric

158 than 4.0 ng/mL after 7 months of ADT, have a poor prognosis, based on historical controls.

159 ive breast tumor is usually accompanied by a poor prognosis because of the metastasis of tumor cells.

160 l carcinoma (OSCC) patients generally have a poor prognosis, because of the invasive nature of these

161 ductal adenocarcinoma (PDAC) has generally a poor prognosis, but recent data suggest that there are m

162 ling within breast cancer is associated with poor prognosis, but regulation of this pathway in breast

163 These diseases have a poor prognosis comparable with endstage cancer and are u

164 ELBW infants with EOD have a very poor prognosis compared to those with LOD.

165 A high expression level of EphA2 predicts poor prognosis, correlating with disease progression and

166 Patients with TNBC suffer a poor prognosis due in part to a lack of molecularly targ

167 (MPNSTs) are a type of rare sarcomas with a poor prognosis due to its highly invasive nature and lim

168 EM has a poor prognosis during the acute phase, despite a publica

169 that CTCF haploinsufficiency also occurs in poor prognosis endometrial clear cell carcinomas and has

170 osis (MALA), a severe medical condition with poor prognosis, especially in individuals with renal dys

171 n NSCLC patients is strongly associated with poor prognosis features that could not be reversed by ra

172 le option to salvage vision in patients with poor prognosis for other corneal procedures.

173 SCCA), lymph node positivity (LNP) indicates poor prognosis for survival and is central to radiothera

174 oduction is a major metabolic feature of the poor prognosis group.

175 ich may give insights into the basis for its poor prognosis, have not been characterized.

176 , identifying DDX5 as an important player in poor prognosis HCC.

177 SALL4 is also re-expressed in poor prognosis HCCs of other etiologies.

178 , is re-expressed by an unknown mechanism in poor prognosis hepatocellular carcinoma (HCC), often ass

179 activity, epithelial-mesenchymal transition, poor prognosis; (iii) CRIS-C: elevated EGFR signalling,

180 Endoscopy helped in identifying poor prognosis in 30 of 64 (46.8%) eyes; thus, further i

181 able of identifying a group of patients with poor prognosis in a "high-MYCN" molecular subtype but no

182 t that nKIFC1 WI an independent biomarker of poor prognosis in AA TNBC patients, potentially due to t

183 ora A-dependent NF-kappaB signaling portends poor prognosis in acute myeloid leukemia (AML) and other

184 Low EZH2 protein levels correlated with poor prognosis in AML patients.

185 Stem cell gene signatures predict poor prognosis in AML patients; however, with few except

186 L), and S100A8 expression has been linked to poor prognosis in AML.

187 giogenic gene expression was associated with poor prognosis in both primary and liver metastasis of C

188 Heat-shock protein 5 (HSPA5) is a marker for poor prognosis in breast cancer patients and has an impo

189 erexpression of MCM2-7 genes correlated with poor prognosis in breast cancer patients.

190 n of ECT2 for which high expression predicts poor prognosis in breast cancer patients.

191 tastasis, pre-metastatic niche formation and poor prognosis in breast cancer patients.

192 gen receptor (ERalpha-36), associated with a poor prognosis in breast cancers.

193 L.ATM and TP53 mutations are associated with poor prognosis in chronic lymphocytic leukaemia (CLL).

194 failure is the major cause of recurrence and poor prognosis in colorectal cancer patients.

195 ation (CRT) therapy and carries a relatively poor prognosis in comparison with HPV-positive disease,

196 ivity signature that is highly predictive of poor prognosis in diverse Myc-associated malignancies an

197 r high expression of Bcl2 is correlated with poor prognosis in gallbladder cancer.

198 with Beclin1 S30 phosphorylation levels and poor prognosis in glioblastoma patients.

199 of purine synthetic enzymes correlated with poor prognosis in glioblastoma patients.

200 ith aggressive characteristics and predicted poor prognosis in HCC patients.

201 3) has been linked to cardiac remodeling and poor prognosis in heart failure of different etiologies.

202 Overexpression of NQO1 is associated with poor prognosis in human cancers including breast, colon,

203 f the immune-privileged niche, and predicted poor prognosis in human CRC patients.

204 ver, high WNT2 expression is associated with poor prognosis in human CRC.

205 correlate with oncogenic KRAS mutations and poor prognosis in human pancreatic cancer, supporting a

206 ow plasma glutamine concentration represents poor prognosis in ICU patients.

207 nd other malignancies and is associated with poor prognosis in leukemia patients.

208 ad4 expression significantly correlated with poor prognosis in LUAD but not in SCC.

209 pression retained their trends in predicting poor prognosis in lung adenocarcinoma (LUAD) but not in

210 is associated with increased metastasis and poor prognosis in lung cancer, but the development of ta

211 elevated FOXC1 expression is associated with poor prognosis in many cancer subtypes, such as basal-li

212 lia, monocytes, and neutrophils is linked to poor prognosis in many cancer types, these reduced immun

213 and its expression is highly correlated with poor prognosis in many human tumors.

214 f intratumoral NRP1(+) Tregs correlates with poor prognosis in melanoma and head and neck squamous ce

215 ies such as 11q deletion are associated with poor prognosis in neuroblastoma.

216 expression by multiple myeloma PCs conferred poor prognosis in newly diagnosed multiple myeloma patie

217 tes with chemoresistance, aggressiveness and poor prognosis in NSCLC patients.

218 and low CIB2 expression was associated with poor prognosis in ovarian cancer patients.

219 malize metabolic aberrations responsible for poor prognosis in ovarian cancer.

220 f soluble VEGFA isoforms are associated with poor prognosis in parallel with improved response to tre

221 levance: Peripheral artery disease confers a poor prognosis in patients undergoing PCI in the setting

222 associated with chemotherapy resistance and poor prognosis in patients with acute myeloid leukemia (

223 inoma is a rare, aggressive skin cancer with poor prognosis in patients with advanced disease.

224 relates with M2 macrophages, metastasis, and poor prognosis in patients with breast cancer.

225 er of tumor progression that correlates with poor prognosis in patients with osteosarcoma.

226 associated with increased tumor volumes and poor prognosis in PDAC especially combined with high lev

227 that IL-35 overexpression is associated with poor prognosis in PDAC patients.

228 e receptor CCR4 in tumors is associated with poor prognosis in several cancers.

229 y relevant as its expression correlates with poor prognosis in several human cancers.

230 chemokine IL-8 (CXCL8) is associated with a poor prognosis in several solid tumors, including epithe

231 lusion, SRCC was an independent predictor of poor prognosis in stage III RC patients, but not in stag

232 , marker chromosomes independently predicted poor prognosis in the AML96 trial </=60 years.

233 Sarcopenia is associated with a poor prognosis in the ICU.

234 uminal A cells, and (3) is associated with a poor prognosis in TNBC breast cancer patients.

235 CDK7 expression as a candidate biomarker of poor prognosis in TNBC, and they offer a preclinical pro

236 between WT1 expression in breast cancer and poor prognosis is potentially due to cancer-related epit

237 testinal cancer, a crucial factor related to poor prognosis is reduced tolerance to chemotherapy indu

238 distinct chromosomal rearrangements to yield poor-prognosis leukemia.

239 lucidate a therapeutic vulnerability in this poor-prognosis leukemia.

240 Problems in accurate diagnosis, poor prognosis, limited clinical therapy, and high morta

241 Poor-prognosis M3-UM divide into subsets with divergent

242 rising from myelodysplastic syndromes have a poor prognosis marked by an increased resistance to chem

243 nosquamous lung tumours, which are extremely poor prognosis, may result from cellular plasticity.

244 osis (AL) with cardiac involvement carries a poor prognosis; median untreated survival is <6 months.

245 cally relevant subtypes: two associated with poor-prognosis monosomy 3 (M3) and two with better-progn

246 ture of acute myeloid leukemia (AML) and its poor prognosis necessitate therapeutic improvement.

247 on and therapy intensification abrogates the poor prognosis of adult ETP-ALL.

248 ptionally repressed in cancers and signifies poor prognosis of breast cancer patients.

249 esistance, immune evasion, and ultimately to poor prognosis of cancer patients.

250 at the invasive tumor front and predicts for poor prognosis of esophageal SCC, shedding light upon th

251 h infiltration of CD11b(+)/CD163(+) TAMs and poor prognosis of GBM patients.

252 due to histone deacetylation associates with poor prognosis of HCC and restored FBP1 expression by HD

253 significantly correlated with metastasis and poor prognosis of HCC patients.

254 at the chemokine receptor is responsible for poor prognosis of hepatocellular carcinoma (HCC) patient

255 been correlated with the aggressiveness and poor prognosis of multiple carcinomas.

256 one demethylases influence the viability and poor prognosis of neuroblastoma cells, where MYC is ofte

257 c peptide (NT-proBNP) concentration predicts poor prognosis of non-CNS cancer patients.

258 OC cells, expression of stem cell genes and poor prognosis of OC patients, suggesting an important r

259 Poor prognosis of ovarian cancer, the deadliest of the g

260 ociated fibroblasts (CAFs) contribute to the poor prognosis of ovarian cancer.

261 One of the main causations of the poor prognosis of pancreatic cancer is the lack of effec

262 Considering the poor prognosis of pancreatic cancer, the detection of a

263 s been associated with tumor progression and poor prognosis of patients with colorectal cancer (CRC).

264 eased protein level has been associated with poor prognosis of several types of cancers.

265 with renal cell carcinoma is associated with poor prognosis of the disease independent of their von H

266 icity seems to be acceptable considering the poor prognosis of the eligible patients.

267 en elevated IL-6 expression in the tumor and poor prognosis of the patients.

268 r, high LPIN1 expression correlates with the poor prognosis of these patients.

269 ound and the patient was explained about the poor prognosis of this condition.

270 tion and provide important insights into the poor prognosis of tumors coexpressing IDO and SLC1A5.

271 th multiple sclerosis, aged 18-50 years with poor prognosis, ongoing disease activity, and an Expande

272 Similar poor prognosis outcomes may be observed with rearrangeme

273 ed with basal-like breast cancer (BLBC) with poor prognosis owing to its role in promoting epithelial

274 f FID in the acute phase of type B IMH has a poor prognosis owing to the high risk of aortic rupture.

275 ancer patients, loss of E6AP associates with poor prognosis, particularly for basal breast cancer.

276 ncreased NRF2 downstream gene expression and poor prognosis, particularly for ER-positive breast canc

277 iding a relevant interface to target in this poor-prognosis pediatric leukemia.

278 cative of chromothripsis and associated with poor prognosis per se and not merely by association with

279 hose suppression in GBM also correlates with poor prognosis, reduces GBM cell migration and invasiven

280 tic program defines a distinct subset with a poor prognosis, representing 30%-40% of human PDAC, char

281 zumab); in contrast, in RAS wt patients with poor-prognosis right-sided tumors, limited efficacy bene

282 TCF genetic deletion occurs predominantly in poor prognosis serous subtype tumours, and this genetic

283 to 4 days may be sufficient in patients with poor-prognosis solid tumors, whereas patients with hemat

284 In the poor prognosis subgroup, median overall survival also di

285 l in all randomly assigned patients and in a poor-prognosis subgroup.

286 a is a karyotypically complex and especially poor-prognosis subtype that accounts for less than 10% o

287 ercome some of the factors associated with a poor prognosis, such at TP53 mutation, and might resolve

288 mmon in acute myeloid leukemia and portend a poor prognosis; thus, new therapeutic strategies are nee

289 parents or family caregivers not to disclose poor prognosis to seriously ill children can be challeng

290 After explaining the condition and the poor prognosis to the patient, an informed consent was o

291 act, most triple-negative breast cancers are poor-prognosis tumors with a complex genomic landscape.

292 nical activity was observed in patients with poor-prognosis tumors.

293 Patients with double-hit lymphomas have a poor prognosis when treated with standard chemoimmunothe

294 defined a group of t(8;21) AML patients with poor prognosis, whereas high N/KRAS mutant allele ratios

295 expression was significantly correlated with poor prognosis while patients with low BMP4 or low Smad4

296 Gastric cancer (GC) has a poor prognosis with wide variation in survival rates acr

297 perative MI was consistently associated with poor prognosis, with a 3.62-fold (95% CI, 2.25-5.82) to

298 amous cell carcinoma (HNSCC) patients have a poor prognosis, with invasion and metastasis as major ca

299 Ovarian cancer has a poor prognosis, with just 40% of patients surviving 5 ye

300 CDK7 protein expression was associated with poor prognosis within the RATHER TNBC cohort (n = 109) a